Is It Safe to Take Retatrutide?

Is it safe to take retatrutide? This is an important question, because retatrutide is an investigational medicine with no marketing authorisation in the UK or anywhere else. Developed by Eli Lilly, it acts on three hormone receptors simultaneously: GLP-1, GIP and glucagon. Because the MHRA has not yet assessed it for safety, quality or efficacy, it cannot be prescribed or supplied outside of an authorised clinical trial. This article explains what the current trial data show about its safety profile, what side effects have been reported, and why obtaining it outside of a trial is neither safe nor legal.

What is retatrutide and what is its regulatory status in the UK?

Retatrutide has no UK marketing authorisation and cannot be prescribed outside an authorised clinical trial. It is an investigational triple agonist targeting GLP-1, GIP and glucagon receptors, developed by Eli Lilly.

Retatrutide holds no marketing authorisation in the UK or anywhere else, meaning it is not a licensed medicine and cannot be prescribed or supplied outside of an authorised clinical trial.^[1][2] It is an investigational drug developed by Eli Lilly that acts on three hormone receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor.^[7][8] This triple agonist mechanism is designed to influence appetite regulation, energy expenditure and glucose metabolism, and it distinguishes retatrutide from currently licensed GLP-1 and dual GIP/GLP-1 receptor agonists.

Because retatrutide has no UK marketing authorisation, the Medicines and Healthcare products Regulatory Agency (MHRA) has not assessed it for safety, quality or efficacy to the standard required for routine clinical use.^[14][15] No approval date can be given, and no timeline for potential authorisation exists in the public domain. People interested in licensed weight-management treatments can discuss the options that are currently available with their GP.

The clinical development programme for retatrutide includes the Phase 3 TRIUMPH trials and the TRANSCEND-T2D-1 study, which has been published in The Lancet.^[18][19] These trials are the only authorised setting in which retatrutide can be administered. Participation is governed by strict eligibility criteria, ethical oversight and a formal study protocol, all of which are designed to protect participants and generate reliable safety data.

What do clinical trials tell us about retatrutide's safety so far?

Clinical trial safety data for retatrutide are still accumulating and no definitive long-term conclusions can yet be drawn. The Phase 2 trial published in the New England Journal of Medicine in 2023 provided early evidence, but was not designed to detect rare or long-term adverse events.

Clinical trial data on retatrutide's safety profile are still accumulating, and no definitive conclusions about its long-term safety can yet be drawn. The most substantial early evidence came from a Phase 2 trial published in The New England Journal of Medicine in 2023, which enrolled adults with obesity over a 48-week period.^[3][4] That trial reported meaningful reductions in body weight across dose groups, but it was not powered or designed to detect rare or long-term adverse events.^[3][4] The Phase 3 TRIUMPH programme and the TRANSCEND-T2D-1 study are providing larger, longer-duration datasets, and the TRANSCEND-T2D-1 results published in The Lancet have added to the understanding of the drug's effects in people with type 2 diabetes.

As with all investigational medicines, the safety data generated so far reflect carefully selected trial populations. Participants are screened against detailed inclusion and exclusion criteria, and people who are pregnant, breastfeeding, planning a pregnancy, or using certain contraceptive methods may be excluded from participation. This means the safety profile observed in trials may not translate directly to broader populations.

Importantly, the absence of a complete long-term safety record is one of the central reasons retatrutide remains investigational. Regulatory agencies including the MHRA require robust evidence across multiple domains, including cardiovascular outcomes, renal effects and tolerability over extended periods, before granting a marketing authorisation. The data available today, while informative, represent an interim picture rather than a settled conclusion.

What side effects have been reported in retatrutide trials?

Gastrointestinal effects including nausea, vomiting, diarrhoea and constipation are the most commonly reported side effects, generally mild to moderate and more frequent at higher doses. Pancreatitis, heart rate increases and gallbladder changes have also been monitored in trials.

The side effects reported in retatrutide trials have broadly resembled those seen with other incretin-based medicines, with gastrointestinal effects being the most commonly described. In the Phase 2 trial published in The New England Journal of Medicine, nausea, vomiting, diarrhoea and constipation were among the most frequently reported adverse events, and these were generally more common at higher doses and during dose escalation periods.^[3][4] Most gastrointestinal effects were described as mild to moderate in severity.

More serious adverse events have also been reported in the trial setting, and these require careful consideration. Pancreatitis is a recognised concern across the GLP-1 receptor agonist class, and participants in retatrutide trials have been monitored for this.^[13] Anyone experiencing severe and persistent abdominal pain should seek prompt medical attention via their GP or, if symptoms are severe, contact NHS 111 for urgent advice. Heart rate increases have also been observed, consistent with findings seen with related medicines.^[7][8]

Changes in gallbladder function, including gallstones, have been noted in trials of medicines in this class, and retatrutide trial participants have been monitored accordingly.^[22][23] Injection site reactions have also been reported. Because retatrutide is still investigational, the full spectrum of its side effects, including rare events that may only emerge in larger populations or over longer durations, is not yet established.

Participants in authorised clinical trials who experience suspected side effects should report them to the trial team under the study protocol. Suspected adverse reactions can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Why can't you take retatrutide outside of a clinical trial in the UK?

Retatrutide cannot be prescribed in the UK because it has no MHRA marketing authorisation, which requires evidence that benefits outweigh risks across safety, quality and efficacy. Even after Phase 3 completion, separate NICE and ICB decisions would determine NHS availability.

Retatrutide cannot be prescribed or supplied outside of an authorised clinical trial in the UK because it has no marketing authorisation from the MHRA. In the UK, a medicine must be assessed and authorised by the MHRA before it can be routinely prescribed, dispensed or sold.^[9][10] That assessment evaluates whether the medicine's benefits outweigh its risks in a defined population, and whether it meets standards for quality and consistent manufacture. Retatrutide has not completed that process.

The clinical trial framework exists precisely to generate the evidence needed for that assessment in a controlled, ethically overseen environment. Trials are conducted under strict protocols that include participant monitoring, dose escalation procedures, safety reviews and independent oversight committees. These safeguards protect participants and ensure that any harms are identified and reported systematically. Outside of that framework, none of those protections exist.

Even if retatrutide were to complete its Phase 3 programme successfully, it would still need to go through a formal regulatory review before the MHRA could grant authorisation. Following any authorisation, NHS availability would depend on separate decisions by bodies such as the National Institute for Health and Care Excellence (NICE) and local Integrated Care Boards (ICBs), which assess clinical and cost-effectiveness for NHS commissioning. These are distinct processes that take additional time.

For people seeking support with weight management now, a GP can discuss licensed treatments that are currently available and appropriate to individual circumstances. Attempting to obtain retatrutide outside of a trial is not a safe or legal route to accessing it.

Is it safe to buy retatrutide online?

It is not safe to buy retatrutide online; any product sold under that name is unlicensed, unverified and may be falsified, contaminated or incorrectly dosed. No legitimate commercial supply exists, as retatrutide cannot legally be dispensed outside an authorised clinical trial.

It is not safe to buy retatrutide online, and any product sold online under that name is not a licensed medicine. Because retatrutide has no marketing authorisation in the UK or any other country, there is no legitimate commercial supply chain for it. Any substance being sold online as retatrutide has not been assessed by the MHRA for safety, quality or efficacy, and its actual contents are unknown. Such products may be falsified, contaminated, incorrectly dosed or entirely different substances from what is claimed on the label.

The risks associated with purchasing unlicensed injectable substances online are serious. Without clinical oversight, there is no monitoring for adverse effects, no dose escalation protocol and no mechanism for identifying or responding to complications. Injecting an unknown substance carries risks of infection, allergic reaction and systemic harm that cannot be quantified because the product's composition is unknown.

The MHRA actively warns the public about the dangers of purchasing medicines from unregulated online sources.^[24] In Great Britain, legitimate online pharmacies are registered with the General Pharmaceutical Council (GPhC), which maintains a public register at pharmacyregulation.org. However, no GPhC-registered pharmacy can legally supply retatrutide, because it is not a licensed product and cannot be dispensed outside of an authorised clinical trial.

Anyone who has purchased or used a product sold as retatrutide online and is experiencing adverse effects should contact their GP or call NHS 111 for urgent advice. If symptoms are severe or life-threatening, call 999 or go to the nearest accident and emergency department immediately.

Frequently Asked Questions